# US 12,109,184 B2 · Personalized methods of treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,109,184 B2
- Document ID: US12109184B2
- Status: Granted
- Kind: B2
- Application number: 17/338,283
- Filed: 2021-06-03
- Published: 2022-02-24
- Granted: 2024-10-08
- Earliest claimed: 2020-06-04
- Assignees: Faeth Therapeutics, Inc.; Cancer Research Technology Limited
- Applicants: Cancer Research Technology Limited; Faeth Therapeutics, Inc.
- Inventors: Oliver D.K. Maddocks
- Web page: https://patentgrep.com/patent/US12109184B2

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are dietary compositions that are substantially devoid of at least cysteine or a salt thereof for use in treating a cancer. The dietary compositions and methods of the disclosure can be used to treat cancers that are MTAP-deficient, alone or in combination with a cancer therapy.

## Claims

### Claim 1

A method for treating a cancer having dysregulated polyamine metabolism in a subject in need thereof, wherein the cancer having dysregulated polyamine metabolism is breast cancer, colorectal cancer, pancreatic cancer, or brain cancer, the method comprising administering to the subject a therapeutically effective amount of a dietary product, wherein:
the dietary product comprises at most about 0.5% (w/w) of cysteine or cystine; the dietary product comprises at least about 7.5% (w/w) of methionine;
the therapeutically effective amount of the dietary product is from about 0.5 g/kg/day to about 1 g/kg/day; and
the subject is undergoing a cancer therapy for the cancer having dysregulated polyamine metabolism.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer having dysregulated polyamine metabolism is breast cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer having dysregulated polyamine metabolism is colorectal cancer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer having dysregulated polyamine metabolism is pancreatic cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer having dysregulated polyamine metabolism has downregulated 5-methylthioadenosine phosphorylase (MTAP) expression.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cancer having dysregulated polyamine metabolism has upregulated adenosylmethionine decarboxylase 1 (AMD1) expression.

### Claim 7 (depends on 1)

The method of claim 1, wherein the administering is oral.

### Claim 8 (depends on 1)

The method of claim 1, wherein the dietary product is devoid of cysteine or cystine.

### Claim 9 (depends on 8)

The method of claim 8, wherein the dietary product is devoid of cysteine or cystine, serine, and glycine.

### Claim 10 (depends on 9)

The method of claim 9, wherein the dietary product is further devoid of tyrosine and arginine.

### Claim 11 (depends on 1)

The method of claim 1, wherein the dietary product comprises more than about 10% (w/w) of methionine.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cancer therapy is radiotherapy.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cancer therapy is chemotherapy.

### Claim 14 (depends on 1)

The method of claim 1, wherein the cancer therapy further comprises administration of a therapeutically effective amount of a polyamine, a precursor of the polyamine, or an analog of the polyamine to the subject.

### Claim 15 (depends on 14)

The method of claim 14, wherein the therapeutically effective amount of the polyamine, the precursor of the polyamine, or the analog of the polyamine is from about 100 mg to about 5000 mg.

### Claim 16 (depends on 1)

The method of claim 1, comprising administering from about 100 mg to about 2000 mg of the methionine.

### Claim 17 (depends on 1)

The method of claim 1, comprising administering at most about 500 mg/day of the cysteine or cystine.

### Claim 18 (depends on 1)

The method of claim 1, wherein administering the dietary product to the subject increases efficacy of the cancer therapy in the subject by at least about 10% as compared to an efficacy of the cancer therapy in a comparable subject receiving the cancer therapy but not the dietary product.

### Claim 19 (depends on 1)

The method of claim 1, wherein administering the dietary product elevates cellular reactive oxygen species (ROS) levels.